- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: PD-L1 high TNBC
Total 25841 results
-
Wuxi People's HospitalRecruitingCancer | PD-L1 Gene MutationChina
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Zhongnan HospitalRecruiting
-
Baodong QinUnknown
-
Shanghai Zhongshan HospitalRecruiting
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Lene Meldgaard KnudsenIO BiotechTerminatedSmoldering Multiple MyelomaDenmark
-
Thomas MarronRecruiting
-
ImmunityBio, Inc.Active, not recruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair DeficiencyUnited States
-
Peking Union Medical College HospitalRecruitingHepatocellular CarcinomaChina
-
Sichuan UniversityNot yet recruitingAdvanced Solid TumorChina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdSunshine Lake Pharma Co., Ltd.Terminated
-
Herlev and Gentofte HospitalUniversity of CopenhagenCompleted
-
Shanghai Zhongshan HospitalRecruitingOesophageal Squamous Cell CarcinomaChina
-
The Second Hospital of Nanjing Medical UniversityUnknownPrimary Hepatocellular Carcinoma
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Sichuan UniversityRecruitingMalignant Ascites | Malignant Peritoneal Effusion | Serous Cavity MetastatisesChina
-
Sichuan UniversityRecruitingPleural Effusion, Malignant | Peritoneal Carcinoma MetastaticChina
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; Gilead SciencesRecruitingBreast Cancer | Triple Negative Breast Cancer | PD-L1 NegativeUnited States
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Genentech, Inc.Completed
-
Lene Meldgaard KnudsenCompleted
-
Shanghai Henlius BiotechRecruitingAdvanced Solid TumorChina
-
Naestved HospitalRecruitingNon-small Cell Lung Cancer | Malignant Pleural EffusionDenmark
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Maastricht Radiation OncologyCompletedProstate Cancer | PD-L1Netherlands
-
Merck Sharp & Dohme LLCRecruitingBladder CancerCanada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
-
Merck Sharp & Dohme LLCActive, not recruitingTriple Negative Breast NeoplasmsBrazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
-
Pyrotech Therapeutics, Inc.RecruitingLocally Advanced or Metastatic Solid TumorsUnited States